| Objective:To explore the change of substance P(SP),neuropeptide Y(NPY),interleukin-2(IL-2)and interleukin-6 (IL-6)plasma levels and cellular immunity before and after antidepression treatment in malignant hematogenesis pantients who were accompany with depressive disorder.Methods:134 malignant hematogenesis pantients were tested by HAMD,49 malignant hematogenesis pantients who were accompany with depressive disorder were randomly taken as experimental group and control group.Both groups accepted commom MD therapy while The patients of experimetal group were treated with antidepressant drug during common therapy additional.SP plasma levels were detected at pre-treatment and past-treatment underwent 4 weeks.The sverity of symptom was evaluated with HAMD before and at 4 weeks after treatment,respectively.Results:1.The score of HAMD in patients of experimetal group decreased and there were significant differences between weeks 2,4 after treatment and before treatment(25.95±8.11 vs 11.83±5.17)(t=9.22,P＜0.01), but there was no significent difference in control group(26.94±3.67 vs 28.00±5.34)(t=0.960,P＞0.05);2.The SP plasma levels of both experimental group and control group didn't significantly change(37.47±23.67vs36.60±24.06);(40.69±13.82vs38.57±19.78)(Z=0.974,1.022;P＞0.05)3.The NPY plasma levels significantly increased after treatment in experimetal group (113.34±80.92vs63.64±62.92)(Z=-2.75,P＜0.01),but there was no significent difference in control group(67.30±63.82 vs 69.42±56.58)(Z=-1.73,P＞0.05);4.Taking the increased NPY plasma level as dependent variable while the decreased score of measuring scales as independent variables,the correlation analysis was conducted and showed that there was no significent corelation between them(r=0.252,P＞0.05)5.CD3,CD4 and CD4/CD8 significantly incresed in experimental group(P＜0.05);CD8 didn't significantly change(67.11±20.55;34.37±11.32;1.16±0.44), (58.58±25.41;25.23±13.01;0.97±0.54)(t=2.740,2.811,3.019, P＜0.05),CD8(33.37±11.36 vs 31.11±11.69)(t=0.973,P＞0.05), while all CD3,CD4,CD8,CD4/CD8 didn't notably change in control group(54.66±24.16;53.39±28.01;39.89±16.35;1.03±0.37 vs 35.05±13.53;20.54±12.64;28.17±10.47;0.99±0.41)(t=0.832,0.901,1.119,0.758;P＞0.05).6.nterleukin-2 and interleukin-6 plasma levels significantly decreased after treatment in experimetal group(16.93±3.54 vs 12.75±2.87);(36.88±11.63 vs 18.46±8.15)(t=2.076,3.015,P＜0.05,P＜0.01),but there was no significent difference in control group(17.10±3.97 vs 16.59±4.02);(33.78±10.35vs37.21±12.47)(t=0.821,0.990, P＞0.05).Conclusion:1.Antidepressive drugs can improve the depressive symptoms of malignant hematogenesis patients: 2.Antidepressive drugs can't change the SP plasma levels.3.Antidepressive drugs can set upNPY plasma levels;4.It seems that the increasing of NPY plasma level could be regarded as one of the biological indexs which response the relief of depressive symptoms.5.Antidepressive treatment can improve the depressive symptoms of malignant hematogenesis patients,and elevate immunity punction of malignant hematogenesis pantients.
|
PDF Full Text Request